Latest Regulatory Filings News

Amaero has released A$2.961 million of restricted cash after renegotiating its EXIM loan, while its proposed US IPO moves through an amended SEC filing. Preliminary September figures show revenue of up to A$5.833 million, but operating cash use remained close to A$9 million.

Genetic Signatures reduced its quarterly operating cash outflow to A$1.0 million after restructuring, while commercial testing began under its Danish hospital contract. The company is also advancing an all-scrip Microba merger, but faces a contested shareholder meeting later this month.

Aspermont has acknowledged that a director’s initial interest notice was lodged around eight months late, after ASX raised possible breaches of its disclosure rules. The company blamed an administrative oversight and said it will tighten appointment procedures, but no penalty or formal breach finding was disclosed.

Albright Metals is moving its Golden Pike project towards a scoping study after defining a 54,200-ounce gold resource at Vail Road, including 22,500 ounces in the Indicated category. The company has also improved its cash position through the quarter, but reported only 1.4 quarters of funding based on current operating outflows.

Ausgold advanced construction, permitting and drilling at its Katanning Gold Project during the September quarter, while its proposed A$776 million takeover by OceanaGold began to reshape the development timetable. The planned end-2026 resource update and final investment decision have both been deferred as shareholders prepare to vote on the scheme.

NewPeak Metals has confirmed two more than 650-metre polymetallic intercepts at Las Opeñas in Argentina, with gold grades increasing towards an untested southwestern target. Phase 2 drilling is due to begin in mid-October, although the explorer reported only 0.81 quarters of funding at its current expenditure rate.

Australian Bond Exchange Holdings improved revenue, reduced its annual loss and sharply cut operating cash outflow in FY2026. Yet with only A$249,000 in cash, net liabilities of A$1.43 million and A$2 million of convertible notes maturing from April 2027, the turnaround remains financially fragile.

American Tungsten & Antimony has submitted a confidential draft Form F-1 to US regulators, moving its proposed Level III ADR listing on Nasdaq into formal review. The company also extended the Del Sol transaction end date by three weeks, leaving both major initiatives progressing but unfinished.

Venari Minerals has issued 37.28 million shares at 8 cents each, completing the second tranche of a previously announced $6.1 million capital raising. The $2.98 million proceeds increase the company’s funding, while also adding to its issued share base.

Micro-X has told ASX it is unaware of any undisclosed information explaining the sharp move in its shares, which rose from $0.030 to $0.045 during 23 September trading. The company pointed to elevated volumes, earlier institutional selling and chairman Patrick O’Brien’s purchase of 1.36 million shares.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

Wrkr has outlined warnings, training and share-repurchase measures after 603,540 shares linked to non-executive director Emma Dobson were sold during a closed trading period. The company says the sale was inadvertent and occurred without Dobson’s knowledge, while committing to tighter controls around related-party trading.